Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Refining checkpoint inhibition in triple-negative breast cancer (TNBC)

Benefits of IO in early and metastatic breast cancer

Date

11 May 2023

Session

Refining checkpoint inhibition in triple-negative breast cancer (TNBC)

Topics

Tumour Site

Breast Cancer

Presenters

Isabel Pimentel

Authors

I. Pimentel

Author affiliations

Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona/ES

Resources

This content is available to ESMO members and event participants.

Login

Resources from the same session

11 May 2023

Who really benefits from IO? Can we identify subsets that benefit and how to measure?

Presenter: Justin Balko

Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)

Resources:

Slides

Webcast

11 May 2023

Can we predict and manage toxicity in the real world?

Presenter: Rebecca Dent

Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)

Resources:

Slides

Webcast

11 May 2023

What’s on the horizon for immunotherapy for TNBC?

Presenter: Giampaolo Bianchini

Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)

Resources:

Slides

Webcast

11 May 2023

Q&A and discussion

Presenter: To be Announced

Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)

Resources:

Webcast